2.6. Paediatric Molecular Tumour Board Discussion

The PMTB was created in November 2014 and composed of paediatric oncologists, pharmacologists, geneticists, pathologists, molecular biologists and bioinformatics. The PMTB established the consensus gene panel for the NGS analysis. After the completion of pathological and genomic studies, results were discussed in periodical meetings in the PMTB and a final report was transferred to the corresponding physician. The workflow was based on previous pilot studies [14,15]. Clinicians were then responsible for deciding if the targeted treatment was indicated at that moment and if the recommendation could be implemented as standard of care, included as off-label treatment or within a clinical trial (usually early phase). The benefit from the recommended treatments was eventually evaluated by clinical and radiological findings. In the patients that were treated in clinical trials RECIST 1.1 criteria were used.